URAC-Accredited Mail Order Pharmacy - $1.5 Million

URAC-Accredited Mail Order Pharmacy represents a strategic acquisition opportunity in the pharmaceutical services sector. This fully operational Class A Community Pharmacy maintains active licensure through 2027 with no disciplinary history and operates as a corporation with comprehensive regulatory compliance.

The facility operates from a 2,700 square foot location under favorable lease terms at $3,800 monthly with utilities included. Current lease expiration presents negotiation opportunities for incoming ownership.

Regulatory Infrastructure:
The pharmacy maintains active federal program participation including Medicaid and Medicare Part B, supported by current DEA registration in good standing. Multi-state licensure across 11 jurisdictions enables nationwide prescription dispensing capabilities.

Accreditation Portfolio:
URAC Mail Order Accreditation provides the foundation for PBM network participation. Additional certifications include VIPPS Internet Pharmacy Accreditation, ACHC Medicare Part B Accreditation, and LegitScript Certified Pharmacy status. This comprehensive accreditation framework reduces regulatory barriers and enables rapid operational scaling.

PBM Network Participation:
Active Mail Order contracts with major pharmacy benefit managers including CVS/Caremark, Humana, and Optum generate predictable recurring revenue through 90-day prescription fulfillment. Express Scripts eligibility remains available for new ownership post-acquisition, presenting additional revenue expansion opportunities.

Operational Systems:
The pharmacy utilizes PioneerRx pharmacy management software with national-level PSAO support and McKesson as primary wholesaler. This established infrastructure ensures operational continuity and supply chain reliability.

Strategic Value Proposition:
The combination of URAC accreditation, multi-state licensure, and active PBM contracts creates immediate revenue generation capability without regulatory approval delays. The mail order model provides scalable growth potential with strong patient retention characteristics inherent in 90-day prescription cycles.

This acquisition opportunity offers immediate market entry into the mail order pharmacy segment with established compliance frameworks, active revenue streams, and expansion-ready infrastructure suitable for telehealth integration, PBM-focused operations, or strategic portfolio addition.